Tradestie Institutional Equity Comparison Engine
AMS vs LH โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LH Overall Edge
LH Captures Institutional Edge (4โ0 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Labcorp Holdings Inc. (LH) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, AMS trades at 44.6x Forward P/E with -7.4% operating margin (+19.2% YoY revenue) versus LH at 19.0x Forward P/E and 11.2% operating margin (+6.9% YoY). In options structure, AMS sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against LH sits in CONSOLIDATION (16th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
LH
AMS 44.6x vs LH 19.0x Fwd P/E
Growth & Margin Winner
LH
Op Margin -7.4% vs 11.2% ยท YoY +19.2% vs +6.9%
Momentum & Technical Winner
LH
1Y -52.2% vs +39.0% ยท 52W Pos 6% vs 98%
Options & Structure Winner
LH
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (16th %ile IV)
AMS
NYSE American
American Shared Hospital Services
Services-Medical Laboratories
$1.07
-0.93% 1D
Market Cap
$7.2M
1M Return
-16.41%
1Y Return
-52.23%
Forward P/E
44.6x
Unified AI Score
33.8 / 100
SELL
Tech 24.0
Fund 38.0
Flow 50.0
Mom 30.0
LH
NYSE
Labcorp Holdings Inc.
Services-Medical Laboratories
$372.46
+0.53% 1D
Market Cap
$30.1B
1M Return
+17.14%
1Y Return
+39.05%
Forward P/E
19.0x
Unified AI Score
40.8 / 100
SELL
Tech 17.0
Fund 35.0
Flow 58.0
Mom 31.1
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AMS -52.23%
LH +39.05%
Spread: +91.28 pp (LH Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | AMS Revenue | LH Revenue | AMS Op. Margin | LH Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $20M | $11.3B | 9.4% | 11.7% | LH |
| FY2019 | $20M | $11.6B | 7.5% | 11.5% | LH |
| FY2020 | $20M | $14.0B | -53.1% | 17.5% | LH |
| FY2021 | $20M | $13.1B | 7.7% | 23.2% | LH |
| FY2022 | $20M | $11.9B | 12.3% | 12.1% | AMS |
| FY2023 | $20M | $12.2B | 1.3% | 6.0% | LH |
| FY2024 | $30M | $13.0B | -9.9% | 8.4% | LH |
| FY2025 | $30M | $13.9B | -12.8% | 9.9% | LH |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AMS | LH | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $7.2M | $30.1B | Larger Scale | LH |
| Trailing P/E Ratio Valuation | 44.6x | 30.4x | Lower Multiple | LH |
| Forward P/E Ratio Valuation | 44.6x | 19.0x | Lower Multiple | LH |
| Revenue Growth (YoY) Growth | +19.2% | +6.9% | Higher Growth | AMS |
| Operating Margin (TTM) Profitability | -7.4% | 11.2% | Higher Margin | LH |
| Net Profit Margin Profitability | -5.8% | 6.9% | Higher Margin | LH |
| Return on Equity (ROE) Capital Efficiency | -12.1% | 11.4% | Higher ROE | LH |
| 52-Week Range Position Momentum | 6% ($1โ$2) | 98% ($245โ$375) | Stronger Trend | LH |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 46% Vol | 0.37ฮฒ ยท 36% Vol | Lower Realized Risk | LH |
| Unified Institutional Score Composite Signal | 33.8 / 100 (SELL) | 40.8 / 100 (SELL) | Higher Composite | LH |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AMS vs LH Buy Guide
AMS
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
LH
CONSOLIDATION
59d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AMS nor LH registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.